# A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis

> **NCT07406035** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.** · enrollment: 156 (estimated)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** TQH3906 Capsule
- **DRUG:** TQH3906 Placebo Capsule
- **DRUG:** Tofacitinib Citrate Tablet 5 mg

## Key facts

- **NCT ID:** NCT07406035
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2027-08
- **Final completion:** 2027-11
- **Target enrollment:** 156 (ESTIMATED)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07406035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07406035, "A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQH3906 Capsules in the Treatment of Active Psoriatic Arthritis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07406035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*